JP5764061B2 - マシテンタン含有治療用組成物 - Google Patents
マシテンタン含有治療用組成物 Download PDFInfo
- Publication number
- JP5764061B2 JP5764061B2 JP2011522608A JP2011522608A JP5764061B2 JP 5764061 B2 JP5764061 B2 JP 5764061B2 JP 2011522608 A JP2011522608 A JP 2011522608A JP 2011522608 A JP2011522608 A JP 2011522608A JP 5764061 B2 JP5764061 B2 JP 5764061B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- butoxy
- isopropyl
- amino
- acceptable salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000001225 therapeutic effect Effects 0.000 title description 10
- 150000003839 salts Chemical class 0.000 claims description 69
- 150000001875 compounds Chemical class 0.000 claims description 50
- 108091006335 Prostaglandin I receptors Proteins 0.000 claims description 36
- 239000000556 agonist Substances 0.000 claims description 36
- QXWZQTURMXZVHJ-UHFFFAOYSA-N selexipag Chemical compound C=1C=CC=CC=1C1=NC(N(CCCCOCC(=O)NS(C)(=O)=O)C(C)C)=CN=C1C1=CC=CC=C1 QXWZQTURMXZVHJ-UHFFFAOYSA-N 0.000 claims description 17
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- OJQMKCBWYCWFPU-UHFFFAOYSA-N ACT-333679 Chemical compound C=1C=CC=CC=1C1=NC(N(CCCCOCC(O)=O)C(C)C)=CN=C1C1=CC=CC=C1 OJQMKCBWYCWFPU-UHFFFAOYSA-N 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 10
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 206010020772 Hypertension Diseases 0.000 claims description 7
- -1 5,6-diphenylpyrazin-2-yl Chemical group 0.000 claims description 6
- 229960002890 beraprost Drugs 0.000 claims description 6
- CTPOHARTNNSRSR-APJZLKAGSA-N beraprost Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC(O)=O CTPOHARTNNSRSR-APJZLKAGSA-N 0.000 claims description 6
- 229960002240 iloprost Drugs 0.000 claims description 6
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 claims description 6
- 206010002383 Angina Pectoris Diseases 0.000 claims description 5
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 5
- 206010019280 Heart failures Diseases 0.000 claims description 5
- 201000001881 impotence Diseases 0.000 claims description 5
- 200000000007 Arterial disease Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 102000009079 Epoprostenol Receptors Human genes 0.000 claims 10
- QRHZUNBGGBTEBL-UHFFFAOYSA-N n-methylsulfonylacetamide Chemical compound CC(=O)NS(C)(=O)=O QRHZUNBGGBTEBL-UHFFFAOYSA-N 0.000 claims 5
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
- 208000028922 artery disease Diseases 0.000 claims 1
- 229960001039 macitentan Drugs 0.000 description 28
- JGCMEBMXRHSZKX-UHFFFAOYSA-N macitentan Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)NCCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 JGCMEBMXRHSZKX-UHFFFAOYSA-N 0.000 description 28
- 102100026476 Prostacyclin receptor Human genes 0.000 description 26
- 241000700159 Rattus Species 0.000 description 14
- 239000000047 product Substances 0.000 description 12
- 229960003841 selexipag Drugs 0.000 description 12
- QPNKYNYIKKVVQB-UHFFFAOYSA-N crotaleschenine Natural products O1C(=O)C(C)C(C)C(C)(O)C(=O)OCC2=CCN3C2C1CC3 QPNKYNYIKKVVQB-UHFFFAOYSA-N 0.000 description 10
- QVCMHGGNRFRMAD-XFGHUUIASA-N monocrotaline Chemical compound C1OC(=O)[C@](C)(O)[C@@](O)(C)[C@@H](C)C(=O)O[C@@H]2CCN3[C@@H]2C1=CC3 QVCMHGGNRFRMAD-XFGHUUIASA-N 0.000 description 10
- QVCMHGGNRFRMAD-UHFFFAOYSA-N monocrotaline Natural products C1OC(=O)C(C)(O)C(O)(C)C(C)C(=O)OC2CCN3C2C1=CC3 QVCMHGGNRFRMAD-UHFFFAOYSA-N 0.000 description 10
- 230000004872 arterial blood pressure Effects 0.000 description 9
- 210000001147 pulmonary artery Anatomy 0.000 description 8
- 102000002045 Endothelin Human genes 0.000 description 6
- 108050009340 Endothelin Proteins 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000005241 right ventricle Anatomy 0.000 description 4
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 4
- 229940118365 Endothelin receptor antagonist Drugs 0.000 description 3
- LMHIPJMTZHDKEW-XQYLJSSYSA-M Epoprostenol sodium Chemical compound [Na+].O1\C(=C/CCCC([O-])=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 LMHIPJMTZHDKEW-XQYLJSSYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002308 endothelin receptor antagonist Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 208000000924 Right ventricular hypertrophy Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229960001123 epoprostenol Drugs 0.000 description 2
- 229960003013 epoprostenol sodium Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000037905 systemic hypertension Diseases 0.000 description 2
- 229960005032 treprostinil Drugs 0.000 description 2
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 description 2
- PTZIVVDMBCVSMR-UHFFFAOYSA-N 2,3-diphenylpyrazine Chemical class C1=CC=CC=C1C1=NC=CN=C1C1=CC=CC=C1 PTZIVVDMBCVSMR-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101000874160 Homo sapiens Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 229960003065 bosentan Drugs 0.000 description 1
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000762 chronic effect Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 102000045360 human SDHB Human genes 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IBPCT/IB2008/053252 | 2008-08-13 | ||
| IB2008053252 | 2008-08-13 | ||
| PCT/IB2009/053553 WO2010018549A2 (en) | 2008-08-13 | 2009-08-12 | Therapeutic compositions containing macitentan |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015119021A Division JP5956026B2 (ja) | 2008-08-13 | 2015-06-12 | マシテンタン含有治療用組成物 |
| JP2015119020A Division JP5956025B2 (ja) | 2008-08-13 | 2015-06-12 | マシテンタン含有治療用組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011530581A JP2011530581A (ja) | 2011-12-22 |
| JP5764061B2 true JP5764061B2 (ja) | 2015-08-12 |
Family
ID=41346591
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011522608A Expired - Fee Related JP5764061B2 (ja) | 2008-08-13 | 2009-08-12 | マシテンタン含有治療用組成物 |
| JP2015119021A Active JP5956026B2 (ja) | 2008-08-13 | 2015-06-12 | マシテンタン含有治療用組成物 |
| JP2015119020A Active JP5956025B2 (ja) | 2008-08-13 | 2015-06-12 | マシテンタン含有治療用組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015119021A Active JP5956026B2 (ja) | 2008-08-13 | 2015-06-12 | マシテンタン含有治療用組成物 |
| JP2015119020A Active JP5956025B2 (ja) | 2008-08-13 | 2015-06-12 | マシテンタン含有治療用組成物 |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US8809334B2 (enEXAMPLES) |
| EP (2) | EP3300729B1 (enEXAMPLES) |
| JP (3) | JP5764061B2 (enEXAMPLES) |
| KR (1) | KR101678699B1 (enEXAMPLES) |
| CN (1) | CN102099026B (enEXAMPLES) |
| AR (1) | AR073031A1 (enEXAMPLES) |
| AU (1) | AU2009280843B2 (enEXAMPLES) |
| BR (1) | BRPI0917661B8 (enEXAMPLES) |
| CA (1) | CA2731370C (enEXAMPLES) |
| CY (2) | CY1119826T1 (enEXAMPLES) |
| DK (2) | DK2315587T3 (enEXAMPLES) |
| ES (2) | ES2652590T3 (enEXAMPLES) |
| HK (1) | HK1253355B (enEXAMPLES) |
| HR (2) | HRP20171917T1 (enEXAMPLES) |
| HU (2) | HUE036071T2 (enEXAMPLES) |
| IL (1) | IL211143A0 (enEXAMPLES) |
| LT (2) | LT3300729T (enEXAMPLES) |
| MA (1) | MA32614B1 (enEXAMPLES) |
| MX (1) | MX350011B (enEXAMPLES) |
| MY (1) | MY178894A (enEXAMPLES) |
| NO (1) | NO2315587T3 (enEXAMPLES) |
| NZ (1) | NZ591601A (enEXAMPLES) |
| PL (2) | PL3300729T3 (enEXAMPLES) |
| PT (2) | PT3300729T (enEXAMPLES) |
| RU (1) | RU2519161C2 (enEXAMPLES) |
| SI (2) | SI2315587T1 (enEXAMPLES) |
| SM (2) | SMT201700592T1 (enEXAMPLES) |
| TW (1) | TWI446911B (enEXAMPLES) |
| WO (1) | WO2010018549A2 (enEXAMPLES) |
| ZA (1) | ZA201101900B (enEXAMPLES) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20120957T1 (hr) | 2005-09-12 | 2012-12-31 | Actelion Pharmaceuticals Ltd. | Stabilni farmaceutski sastav koji sadrži pirimidin-sulfamid |
| MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
| USRE46364E1 (en) * | 2008-02-28 | 2017-04-11 | Nippon Shinyaku Co., Ltd. | Fibrosis inhibitor |
| DK2315587T3 (en) | 2008-08-13 | 2018-01-02 | Actelion Pharmaceuticals Ltd | THERAPEUTIC COMPOSITIONS CONTAINING MACITENTAN |
| WO2014110491A1 (en) | 2013-01-11 | 2014-07-17 | Theratrophix Llc | Prodrugs of treprostinil |
| US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US9643911B2 (en) | 2015-06-17 | 2017-05-09 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US9794795B1 (en) | 2016-04-29 | 2017-10-17 | Corning Optical Communications Wireless Ltd | Implementing a live distributed antenna system (DAS) configuration from a virtual DAS design using an original equipment manufacturer (OEM) specific software system in a DAS |
| RU2019121646A (ru) | 2016-12-14 | 2021-01-15 | Респира Терапьютикс, Инк. | Способы и композиции для лечения легочной гипертензии и других заболеваний легких |
| US20200085741A1 (en) * | 2018-09-14 | 2020-03-19 | Pharmosa Biopharm Inc. | Pharmaceutical composition for controlled release of weak acid drugs and uses thereof |
| DK3897646T3 (da) | 2018-12-21 | 2024-07-01 | Actelion Pharmaceuticals Ltd | Macitentan til behandling af pulmonal arteriel hypertension |
| TW202042818A (zh) | 2019-01-25 | 2020-12-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療慢性血栓性肺高血壓之醫藥組成物 |
| EP4065119B1 (en) | 2019-11-29 | 2024-09-04 | Actelion Pharmaceuticals Ltd | Initial triple combination therapy with macitentan, tadalafil, and selexipag for treating pulmonary arterial hypertension |
| JP2023507626A (ja) | 2019-12-16 | 2023-02-24 | テナックス・セラピューティクス，インコーポレイテッド | 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン |
| CA3240614A1 (en) | 2021-12-31 | 2023-07-06 | Stuart Rich | Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4539333A (en) | 1976-05-11 | 1985-09-03 | Burroughs Wellcome Co. | Prostacyclin, methods of using and method of making |
| DE2845770A1 (de) | 1978-10-19 | 1980-04-30 | Schering Ag | Neue prostacyclin-derivate und verfahren zu ihrer herstellung |
| JPS58124778A (ja) | 1982-01-20 | 1983-07-25 | Toray Ind Inc | ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体 |
| US4683330A (en) | 1984-03-08 | 1987-07-28 | The Upjohn Company | Interphenylene carbacyclin derivatives |
| CA2431675C (en) | 2000-12-18 | 2011-11-08 | Actelion Pharmaceuticals Ltd. | Novel sulfamides and their use as endothelin receptor antagonists |
| SK8192003A3 (en) * | 2000-12-19 | 2003-10-07 | Merck Patent Gmbh | Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives |
| DE10100426B4 (de) | 2001-01-08 | 2006-04-06 | Steag Hamatech Ag | Verfahren und Vorrichtung zum Zusammenfügen von Substraten |
| TWI316055B (enEXAMPLES) * | 2001-04-26 | 2009-10-21 | Nippon Shinyaku Co Ltd | |
| WO2004017993A1 (en) | 2002-08-12 | 2004-03-04 | Actelion Pharmaceuticals Ltd | Combination of prostacyclin or prostacyclin analogues and endothelin receptor antagonists for the treatment of pulmonary arterial hypertension |
| JP4769460B2 (ja) | 2002-12-02 | 2011-09-07 | アクテリオン ファーマシューティカルズ リミテッド | 新規スルファミド類 |
| US20050101608A1 (en) * | 2003-09-24 | 2005-05-12 | Santel Donald J. | Iloprost in combination therapies for the treatment of pulmonary arterial hypertension |
| TW200628467A (en) | 2004-11-11 | 2006-08-16 | Actelion Pharmaceuticals Ltd | Novel sulfamides |
| HRP20120957T1 (hr) | 2005-09-12 | 2012-12-31 | Actelion Pharmaceuticals Ltd. | Stabilni farmaceutski sastav koji sadrži pirimidin-sulfamid |
| AR062501A1 (es) | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
| KR20100132489A (ko) | 2008-02-20 | 2010-12-17 | 액테리온 파마슈티칼 리미티드 | 난소암을 치료하기 위하여 파클리탁셀을 포함하는 조합 |
| DK2315587T3 (en) | 2008-08-13 | 2018-01-02 | Actelion Pharmaceuticals Ltd | THERAPEUTIC COMPOSITIONS CONTAINING MACITENTAN |
-
2009
- 2009-08-12 DK DK09786912.7T patent/DK2315587T3/en active
- 2009-08-12 JP JP2011522608A patent/JP5764061B2/ja not_active Expired - Fee Related
- 2009-08-12 RU RU2011109084/15A patent/RU2519161C2/ru active
- 2009-08-12 HR HRP20171917TT patent/HRP20171917T1/hr unknown
- 2009-08-12 SM SM20170592T patent/SMT201700592T1/it unknown
- 2009-08-12 EP EP17191033.4A patent/EP3300729B1/en not_active Revoked
- 2009-08-12 WO PCT/IB2009/053553 patent/WO2010018549A2/en active Application Filing
- 2009-08-12 PL PL17191033T patent/PL3300729T3/pl unknown
- 2009-08-12 NO NO09786912A patent/NO2315587T3/no unknown
- 2009-08-12 AU AU2009280843A patent/AU2009280843B2/en active Active
- 2009-08-12 HU HUE09786912A patent/HUE036071T2/hu unknown
- 2009-08-12 ES ES09786912.7T patent/ES2652590T3/es active Active
- 2009-08-12 SM SM20190740T patent/SMT201900740T1/it unknown
- 2009-08-12 LT LTEP17191033.4T patent/LT3300729T/lt unknown
- 2009-08-12 PT PT171910334T patent/PT3300729T/pt unknown
- 2009-08-12 CA CA2731370A patent/CA2731370C/en active Active
- 2009-08-12 CN CN2009801279936A patent/CN102099026B/zh not_active Expired - Fee Related
- 2009-08-12 SI SI200931770T patent/SI2315587T1/en unknown
- 2009-08-12 EP EP09786912.7A patent/EP2315587B1/en not_active Revoked
- 2009-08-12 AR ARP090103113A patent/AR073031A1/es not_active Application Discontinuation
- 2009-08-12 PT PT97869127T patent/PT2315587T/pt unknown
- 2009-08-12 TW TW098127151A patent/TWI446911B/zh active
- 2009-08-12 KR KR1020117003547A patent/KR101678699B1/ko active Active
- 2009-08-12 SI SI200932016T patent/SI3300729T1/sl unknown
- 2009-08-12 HU HUE17191033A patent/HUE047767T2/hu unknown
- 2009-08-12 US US13/058,639 patent/US8809334B2/en active Active
- 2009-08-12 LT LTEP09786912.7T patent/LT2315587T/lt unknown
- 2009-08-12 NZ NZ591601A patent/NZ591601A/xx unknown
- 2009-08-12 BR BRPI0917661A patent/BRPI0917661B8/pt not_active IP Right Cessation
- 2009-08-12 MY MYPI2011000637A patent/MY178894A/en unknown
- 2009-08-12 ES ES17191033T patent/ES2763176T3/es active Active
- 2009-08-12 MX MX2011001625A patent/MX350011B/es active IP Right Grant
- 2009-08-12 DK DK17191033.4T patent/DK3300729T3/da active
- 2009-08-12 PL PL09786912T patent/PL2315587T3/pl unknown
-
2011
- 2011-02-10 IL IL211143A patent/IL211143A0/en active IP Right Grant
- 2011-03-07 MA MA33675A patent/MA32614B1/fr unknown
- 2011-03-11 ZA ZA2011/01900A patent/ZA201101900B/en unknown
-
2014
- 2014-07-18 US US14/335,657 patent/US9173881B2/en active Active
-
2015
- 2015-06-12 JP JP2015119021A patent/JP5956026B2/ja active Active
- 2015-06-12 JP JP2015119020A patent/JP5956025B2/ja active Active
- 2015-10-02 US US14/873,787 patent/US9597331B2/en active Active
-
2018
- 2018-01-19 CY CY20181100074T patent/CY1119826T1/el unknown
- 2018-10-03 HK HK18112650.6A patent/HK1253355B/en not_active IP Right Cessation
-
2019
- 2019-12-06 HR HRP20192204TT patent/HRP20192204T1/hr unknown
-
2020
- 2020-01-08 CY CY20201100016T patent/CY1122641T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5764061B2 (ja) | マシテンタン含有治療用組成物 | |
| EP3043789B1 (en) | Use of a ppar-delta agonists for treating muscle atrophy | |
| US20070203202A1 (en) | Methods of reducing adverse events associated with pirfenidone therapy | |
| US20080287508A1 (en) | Altering pharmacokinetics of pirfenidone therapy | |
| KR20080035608A (ko) | 액상 제제 | |
| TW202228682A (zh) | 使用右美托咪啶(dexmedetomidine)鹽酸鹽治療躁鬱症及精神病 | |
| JP2016503803A (ja) | 酢酸グラチラマーの経粘膜送達 | |
| EP4146172A1 (en) | Niclosamide formulations and methods of use | |
| HK1157221B (en) | Therapeutic compositions containing macitentan | |
| HK1157221A (en) | Therapeutic compositions containing macitentan | |
| JP7497868B2 (ja) | アンジオテンシン変換酵素２の発現抑制剤、および、アンジオテンシン変換酵素２を受容体とするウイルスに対する抗ウイルス剤 | |
| CN120641096A (zh) | 色胺前药的改进型药代动力学特性 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120705 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131030 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140122 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140415 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141203 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150223 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150312 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150513 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150612 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5764061 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |